BUILD 3: Bosentan Use in Interstitial Lung Disease
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group,
placebo-controlled, event-driven, group sequential, phase III superiority study. The primary
objective is to demonstrate that bosentan delays disease worsening or death in patients with
Idiopathic Pulmonary Fibrosis.